Codexis (NASDAQ:CDXS) Releases Earnings Results, Beats Estimates By $0.01 EPS

Codexis (NASDAQ:CDXS) posted its earnings results on Tuesday. The biotechnology company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.01, FiscalAI reports. The company had revenue of $14.91 million for the quarter, compared to analyst estimates of $13.82 million. Codexis had a negative return on equity of 68.09% and a negative net margin of 40.97%.

Here are the key takeaways from Codexis’ conference call:

• Financial flexibility improved: Second-quarter revenue was $14.9 million, while product gross margin rose to 73%; management now expects full-year 2026 gross margin in the high 60s. A recent financing generated approximately $25 million in net proceeds, extending the projected cash runway through 2028.
• ECO Synthesis gained commercial traction: New data on precise phosphorothioate stereochemistry and starterless synthesis generated strong customer interest, with several engagements advancing and one of three CDMO partners entering negotiations for a long-term commercial contract.
• RNA manufacturing scale-up remains on track: Codexis plans to begin construction of its approximately $25 million GMP facility after permitting, advance ECO Synthesis production from hundreds of grams toward 500 grams by year-end and eventually kilogram scale, and support customer IND filings and clinical trials.
• Small-molecule biocatalysis is returning to growth: The business remains profitable and benefits from higher-margin products, four partner drug approvals in 2026, a label expansion, and 15 programs in Phase II or III; management sees potential for high-single-digit long-term growth, although sales can remain lumpy.
• Execution and commercialization risks remain: Revenue declined modestly year over year to $14.9 million, the company continues to post quarterly losses, and its $72 million–$76 million 2026 revenue target requires a significant second-half ramp. ECO Synthesis also still faces technical scale-up, customer adoption and contract-conversion risks.

Codexis Stock Performance

Shares of Codexis stock traded down $0.02 during mid-day trading on Tuesday, hitting $1.48. 867,577 shares of the stock were exchanged, compared to its average volume of 1,593,090. Codexis has a 12 month low of $0.96 and a 12 month high of $3.87. The company has a 50-day simple moving average of $2.18 and a 200 day simple moving average of $1.98. The company has a market capitalization of $134.53 million, a P/E ratio of -4.00 and a beta of 2.54. The company has a debt-to-equity ratio of 0.94, a quick ratio of 5.23 and a current ratio of 5.36.

Institutional Trading of Codexis

A number of institutional investors and hedge funds have recently modified their holdings of the business. State of Wyoming bought a new stake in Codexis during the second quarter worth $25,000. Victory Capital Management Inc. bought a new position in Codexis in the 3rd quarter valued at $25,000. CIBC Bancorp USA Inc. purchased a new stake in shares of Codexis during the 3rd quarter valued at $26,000. BNP Paribas Financial Markets increased its position in shares of Codexis by 93.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 16,608 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 8,038 shares during the last quarter. Finally, Persistent Asset Partners Ltd bought a new stake in shares of Codexis during the 4th quarter worth $45,000. 78.54% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently commented on CDXS. Weiss Ratings raised Codexis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 20th. Wall Street Zen downgraded shares of Codexis from a “buy” rating to a “hold” rating in a report on Sunday, May 3rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Codexis in a research note on Wednesday, June 17th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Codexis currently has an average rating of “Hold” and a consensus price target of $5.00.

Codexis Company Profile

Codexis, Inc, headquartered in Redwood City, California, is a leading protein engineering company focused on the development of innovative enzyme solutions for pharmaceutical, food and beverage, and specialty chemical applications. The company’s proprietary directed evolution platform, CodeEvolver®, enables the rapid identification and optimization of enzymes with enhanced activity, selectivity and stability. By leveraging this technology, Codexis provides custom biocatalysts designed to improve manufacturing efficiency and reduce environmental impact.

Since its founding in 2002, Codexis has expanded its capabilities from early-stage research to commercial-scale production.